3-[4-(1H-imidazol-1-yl)phenyl]-N-phenyl-1H-pyrazole-1-carboxamide | 321385-59-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[4-(1H-imidazol-1-yl)phenyl]-N-phenyl-1H-pyrazole-1-carboxamide
• 英文别名: 3-(4-imidazol-1-ylphenyl)-N-phenylpyrazole-1-carboxamide
• CAS: 321385-59-5
• 化学式: C₁₉H₁₅N₅O
• 分子量: 329.4
• InChiKey: FJNHAVXYEQSETJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PEPTIDOMIMETIC MODULATORS OF CELL ADHESION
  申请人：Gour J. Barbara

  公开号：US20080081831A1

  公开（公告）日：2008-04-03

  Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
• Bmp Gene and Fusion Protein
  申请人：Hidaka Chisa

  公开号：US20080260829A1

  公开（公告）日：2008-10-23

  This invention relates to BMP fusion genes, BMP fusion proteins. The invention further relates to methods for treatment using BMP fusion genes and BMP fusion proteins. Additionally, the invention relates to BMP fusion gene and BMP fusion protein pharmaceutical compositions.
• US7268115B2
  申请人：——

  公开号：US7268115B2

  公开（公告）日：2007-09-11
• US7446120B2
  申请人：——

  公开号：US7446120B2

  公开（公告）日：2008-11-04
• [EN] CYCLIC UREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EFFECTIVE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS<br/>[FR] COMPOSES D'UREE CYCLIQUES COMME INHIBITEURS D'EPOXYDE HYDROLASE SOLUBLES EFFECTIFS DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2007106706A1

  公开（公告）日：2007-09-20

  [EN] Disclosed are methods of using soluble epoxide hydrolase (sEH) inhibitors for treating diseases related to cardiovascular disease.
  [FR] La présente invention concerne des procédés d'utilisation d'inhibiteurs d'époxyde hydrolase soluble (sEH) pour traiter des maladies liées à une maladie cardiovasculaire.